Highest-materiality recent filing
Quest Diagnostics Q2 revenue up 10.2% to $3.04B; raises FY2026 guidance
Q2 revenue $3.04B (+10.2% YoY), organic growth 10.0%.
Quest Diagnostics Q1 revenue $2.90B (+9.2%), raises FY2026 EPS and revenue guidance
Reported diluted EPS $2.24 (+15.5%); adjusted diluted EPS $2.50 (+13.1%).
Quest Diagnostics Q4 rev $2.81B (+7.1%), adj EPS $2.42 (+8.5%); raises dividend 7.5%
FY2025 revenue $11.04B (+11.8%), reported EPS $8.75 (+13.8%), adjusted EPS $9.85 (+10.3%).
Quest Diagnostics Q3 revenue $2.82B (+13.1%), raises FY2025 adjusted EPS guidance to $9.76–$9.84
Q3 reported diluted EPS $2.16 (+8.5%); adjusted diluted EPS $2.60 (+13.0%) vs $2.30 prior year.
Q2 revenue $2.76B, up 15.2% YoY; organic revenue growth 5.2%.
Quest Diagnostics Q1 revenue up 12.1% to $2.65B, raises FY reported EPS guidance
Q1 net revenues $2.65B (+12.1% YoY); reported diluted EPS $1.94 (+12.8%), adjusted diluted EPS $2.21 (+8.3%).
Q4 revenue $2.62B (+14.5% YoY); reported diluted EPS $1.95 (+14.7%); adjusted diluted EPS $2.23 (+3.7%).
Quest Diagnostics Q3 revenue +8.5% to $2.49B, raises FY revenue guidance
Q3 revenue $2.49B (+8.5% YoY); reported EPS $1.99 (+1.5%); adjusted EPS $2.30 (+3.6%).
Quest Diagnostics prices $1.85B in senior notes to fund LifeLabs acquisition
Issued $400M at 4.600% due 2027, $600M at 4.625% due 2029, $850M at 5.000% due 2034.
Quest Diagnostics beats Q2 estimates, raises full-year guidance; announces four acquisitions
Q2 revenues $2.397B (+2.5% YoY); reported EPS $2.03 (-1% YoY), adjusted EPS $2.35 (+2.2% YoY)
Quest Diagnostics to acquire LifeLabs from OMERS for C$1.35B (~US$985M)
Cash purchase price of ~C$1.35B (US$985M) including net debt, funded with cash and debt.
Quest Diagnostics Q1 revenue $2.37B (+1.5% YoY); raises full-year adjusted EPS to $8.72-$8.97
Revenue $2.366B, up 1.5% YoY; base business revenue grew nearly 6%.
Quest Diagnostics Q4 2023 adjusted EPS $2.15, +8.6%; base business revenue +4.7%
Q4 reported net revenue $2.29B (-1.9% YoY); base business revenue $2.25B (+4.7%).
Quest Diagnostics issues $750M of 6.400% senior notes due 2033
$750M aggregate principal; 6.400% coupon; mature Nov 30, 2033; interest paid semi-annually May 30 & Nov 30.
Quest Diagnostics Q3 revenue $2.30B (-7.7% YoY); adjusted EPS $2.22; base business up 4.6%
Reported diluted EPS $1.96 (down 9.7% YoY); adjusted diluted EPS $2.22 (down 5.9% YoY).
Quest Diagnostics Q2 revenue $2.34B down 4.7% YoY; base business up 9.5%; raises FY revenue guidance
Q2 reported EPS $2.05 (+4.6% YoY); adjusted EPS $2.30 (-2.5% YoY).
Quest Diagnostics Q1 revenue falls 10.7% to $2.33B; acquires Haystack Oncology for $300M
Q1 net revenue $2.33B, down 10.7% YoY; base business revenue up 10% to $2.21B.
Reiterates 2023 guidance: revenue $8.83B-$9.03B, base business +2.6%-3.8%, adjusted EPS $8.40-$9.00.
Quest CEO James Davis elected Chairman of Board effective April 1
James E. Davis, CEO and President, elected Chairman effective April 1, 2023.
Quest Diagnostics Q4 revenue down 15% to $2.33B; base business up 6.3%; raises dividend 7.6%
Q4 reported net revenues $2.33B (-15% YoY); base business revs $2.15B (+6.3%); COVID revs $184M (-74.6%).
James E. Davis succeeds Steve Rusckowski as CEO and President effective November 1, 2022.
Quest Diagnostics increases CEO Davis's salary to $1.1M, grants $5M equity upon promotion
CEO Davis base salary raised to $1.1M, target annual incentive 150% of salary, effective Nov 1, 2022.
Q3 2022 net revenues $2.49B, down 10.4% YoY; base business revenues $2.17B, up 5.1% YoY; COVID-19 testing $316M, down 55.4%.
Quest Diagnostics Q2 rev $2.45B (-3.8% YoY); raises FY22 adj EPS guidance to $9.55-$9.95
Q2 reported diluted EPS $1.96 (down 60.5% YoY); adjusted diluted EPS $2.36 (down 25.8% YoY).
Stephen H. Rusckowski retires as CEO/President effective Nov 1, 2022; James E. Davis becomes CEO.
Quest Diagnostics names Sam Samad as EVP & CFO, effective July 25, 2022
Samad joins from Illumina (CFO since 2017); start date July 11, CFO role effective July 25.
Quest Diagnostics raises FY2022 guidance after Q1 base business grows 6.3%; adjusted EPS $3.22
Q1 net revenues $2.61B (-4.0% YoY); base business revenues $2.01B (+6.3% YoY); COVID revenues $599M (-27.6%).
CFO Mark Guinan received annual equity grant of $1.12M, half of 2021 grant, with accelerated vesting upon retirement.
Quest Diagnostics appoints James E. Davis as CEO-elect; CFO Mark Guinan to retire in 2022
James E. Davis appointed CEO-elect effective Feb. 3, 2022; to become CEO and President on Nov. 1, 2022.
Fourth quarter revenues $2.74B (-8.6% YoY); diluted EPS $3.12 reported, $3.33 adjusted (-25.7% adj.).
Quest Diagnostics Q4 rev $2.74B (-9% YoY); FY EPS beats outlook; 2022 guidance raised
Preliminary Q4 2021 revenue ~$2.74B, down 9% from $3.00B in Q4 2020.
On May 16, 2024, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board’s Governance Committee, elected Robert B. Carter to the Board.
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
Mr. Davis became Chief Executive Officer and President of the Company, and Stephen H. Rusckowski remains Chairman of the Company
Mr. Davis became Chief Executive Officer and President of the Company, and Stephen H. Rusckowski remains Chairman of the Company
elected James E. Davis to fill the resulting vacancy
On October 28, 2022, the Compensation Committee (the “Committee”) of the Board of Directors of Quest Diagnostics Incorporated (the “Company”) approved an updated compensation package for Mr. Davis, reflecting Mr. Davis becoming Chief Executive Officer and President of the Company.
Mr. Rusckowski’s arrangements in connection with his retirement as Chief Executive Officer and President on November 1, 2022 and his service as Executive Chairman of the Company until March 31, 2023.
On June 9, 2022, Quest Diagnostics Incorporated (the “Company”) announced that Sam Samad will become Executive Vice President and Chief Financial Officer of the Company.
Mr. Samad succeeds Mark Guinan, who, in February 2022, announced his decision to retire.
Max materiality 0.85 · Median 0.70 · Most common event earnings